Genprex, Inc. – NASDAQ:GNPX

Add to watchlist

$0.173

-0.70

-80.19%

Market closed

Open in about 14 hours

-54.43%

month

-54.43%

quarter

+302.30%

year

Market Cap	7.84M
Enterprise value	N/A

P/E	-1.74
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	N/A
Price/Book	1.72
PEG ratio	-0.02
EPS	-19.18

Revenue	N/A
EBITDA	-27.77M
Income	-27.62M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Genprex, Inc. (NASDAQ:GNPX): Profit margin
Jun 2023	0	-7.98M
Sep 2023	0	-7.74M
Dec 2023	23.15K	-5.92M	-25607.89%
Mar 2024	0	-5.96M

Genprex Financials Estimate

Q Y

Genprex, Inc. (NASDAQ:GNPX): Analyst Estimates
Mar 2024	0	-5.96M
Sep 2025	0	-965.83K
Oct 2025	0	-1.03M
Dec 2025	0	-938.57K

Analysts Price target
Financials & Ratios estimates

Genprex, Inc. (NASDAQ:GNPX): Earnings per share (EPS)
2022-11-14	-0.12	-0.13

Genprex, Inc. (NASDAQ:GNPX): Debt to assets
Jun 2023	15911119	3.86M	24.26%
Sep 2023	16643625	4.33M	26.06%
Dec 2023	10670592	3.25M	30.5%
Mar 2024	12564591	3.80M	30.31%

Genprex, Inc. (NASDAQ:GNPX): Cash Flow
Jun 2023	-8.10M	-20K	0
Sep 2023	-4.73M	-21.75K	6.51M
Dec 2023	-4.96M	-9.83K	10
Mar 2024	-5.29M	-15.82K	6.79M

Genprex alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Genprex, Inc. (NASDAQ:GNPX): Employee count
Aug 2023	28
Sep 2023	30
Oct 2023	30
Nov 2023	30
Dec 2023	31
Jan 2024	31
Feb 2024	31
Mar 2024	31
Apr 2024	31
May 2024	26
Jun 2024	26
Jul 2024	26

Genprex
Hedge Funds Holdings Q1 2023

2.28% -6.29%

of GNPX is owned by hedge funds

23 -21

hedge funds hold GNPX stock

1.07M -2.96M

shares is hold by hedge funds

GNPX hedge funds holdings changes

Genprex, Inc. (NASDAQ:GNPX): Insider trades (number of shares)
Period	Buy	Sel
Apr 2023	39000	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	21 Apr 2023	VACZY CATHERINE M officer: EVP GC C..	Common Stock	20,000	$1.07	$21,480
Purchase	21 Apr 2023	VARNER JOHN RODNEY director, officer..	Common Stock	19,000	$1.06	$20,045
Option	28 Jul 2022	CONFER RYAN M. officer: Chief Financial Officer officer: Chief Financial Officer	Stock Option (right to buy)	116,973	$0.02	$1,755
Option	28 Jul 2022	CONFER RYAN M. officer: Chief Financial Officer officer: Chief Financial Officer	Common Stock	116,973	$0.02	$1,755
Purchase	5 Apr 2021	LONGNECKER BRENT M director director	Common Stock	15,000	$4.15	$62,250
Purchase	5 Sep 2019	VARNER JOHN RODNEY director, officer..	Common Stock	1,800	N/A	N/A
Purchase	30 Jul 2018	PHAM JULIEN L officer: President & COO officer: President & COO	Common Stock	500	N/A	N/A
Purchase	29 Mar 2018	NANCE CHRISTY M. 10 percent owner 10 percent owner	Common Stock	50,000	N/A	N/A
Purchase	29 Mar 2018	ROTH JACK A 10 percent owner 10 percent owner	Common Stock	40,000	$5	$200,000
Purchase	29 Mar 2018	VARNER JOHN RODNEY director, officer..	Common Stock	10,000	$5	$50,000

Genprex
Executives

Insider	Age	Compensation
Mr. John Rodney Varner (1957) Co, Founder, Pres, Chief Executive Officer, Sec. & Chairman	68	$750,940
Ms. Catherine M. Vaczy (1961) Executive Vice President, Gen. Counsel & Chief Strategy Officer	64	$646,020
Mr. Ryan M. Confer M.S. (1982) Chief Financial Officer	43	$522,530

Genprex
Latest News

Monday, 16 December 2024
09:15	Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer	prnewswire.com
Wednesday, 20 November 2024
09:29	Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer	prnewswire.com
Tuesday, 5 November 2024
09:29	Genprex Collaborators Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting	prnewswire.com
Thursday, 31 October 2024
09:29	Genprex to Participate in 2024 BIO Europe Conference	prnewswire.com
Monday, 28 October 2024
09:29	Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer, Mesothelioma and Glioblastoma	prnewswire.com
Thursday, 24 October 2024
09:29	Genprex Announces Sponsored Research Agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive	prnewswire.com
Tuesday, 15 October 2024
09:29	Genprex Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer	prnewswire.com
Thursday, 10 October 2024
09:29	Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics	prnewswire.com
Monday, 7 October 2024
09:29	Genprex Collaborators to Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting	prnewswire.com
Monday, 23 September 2024
09:29	Genprex Featured in CEO/CFO Magazine Discussing Novel Gene Therapies for Cancer and Diabetes	prnewswire.com
Thursday, 19 September 2024
09:29	Genprex Announces Formation of Mesothelioma Clinical Advisory Board	prnewswire.com
Monday, 9 September 2024
09:29	Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics	prnewswire.com
Wednesday, 4 September 2024
09:29	Genprex Announces Plans to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 Diabetes	prnewswire.com
Tuesday, 3 September 2024
08:15	Genprex to Present and Participate at Upcoming September Investor and Industry Conferences	prnewswire.com
Thursday, 15 August 2024
09:30	Genprex Releases New Video Featuring Chief Medical Officer Discussing Positive Patient Outcomes in Two Lung Cancer Clinical Trials	prnewswire.com
Wednesday, 14 August 2024
09:25	Genprex Announces Positive Clinical Study Updates from Acclaim-1 and Acclaim-3 Phase 1/2 Clinical Trials in Lung Cancer	prnewswire.com
Tuesday, 13 August 2024
08:31	Genprex Granted Patent in Singapore for Reqorsa® Gene Therapy with PD-1 Antibodies to Treat Cancers	prnewswire.com
Thursday, 8 August 2024
08:30	Genprex to Present at the August Sidoti Microcap Conference	prnewswire.com
Thursday, 27 June 2024
08:31	Genprex Issues Stockholder Letter and Provides 2024 Corporate Update	prnewswire.com
Thursday, 30 May 2024
08:31	Genprex to Present at the 2024 BIO International Convention	prnewswire.com
Tuesday, 14 May 2024
08:31	Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer	prnewswire.com
Monday, 13 May 2024
08:31	Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors	prnewswire.com
Wednesday, 8 May 2024
18:08	Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner	prnewswire.com
Wednesday, 1 May 2024
08:31	Genprex to Present and Participate at Upcoming May Investor and Industry Conferences	PRNewsWire
Thursday, 4 April 2024
10:01	Genprex (GNPX) Expands SCLC Study of Key Candidate, Stock Up	Zacks Investment Research
Tuesday, 6 February 2024
07:30	Genprex to Present at Upcoming BIO CEO & Investor Conference	PRNewsWire
Wednesday, 4 October 2023
12:00	Genprex to Present Data on the Use of REQORSA® for the Treatment of Lung Cancers at 2023 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics	PRNewsWire
Monday, 4 September 2023
13:32	GENPREX (GNPX) Upgraded to Buy: Here's What You Should Know	Zacks Investment Research
Wednesday, 5 July 2023
09:47	Genprex granted Chinese patent for lead drug candidate REQORSA with PD-1 antibodies to treat cancers	Proactive Investors
Wednesday, 28 June 2023
09:31	Genprex shares rise as FDA grants third Fast Track Designation for small cell lung cancer therapeutic REQORSA	Proactive Investors

Ideas & Opinions

Seeking Alpha 8 Mar 2023

Genprex's Gene Therapy: Potential Breakthrough For Diabetes And Lung Cancer
Seeking Alpha 19 Nov 2021

Genprex: Limited Clinical Data To Justify Risk

Frequently Asked Questions (FAQ)

What's the price of Genprex stock today?

One share of Genprex stock can currently be purchased for approximately $0.17.
When is Genprex's next earnings date?

Unfortunately, Genprex's (GNPX) next earnings date is currently unknown.
Does Genprex pay dividends?

No, Genprex does not pay dividends.
How much money does Genprex make?

Genprex has a market capitalization of 7.84M. Genprex made a loss 30.86M US dollars in net income (profit) last year or -$0.13 on an earnings per share basis.
What is Genprex's stock symbol?

Genprex, Inc. is traded on the NASDAQ under the ticker symbol "GNPX".
What is Genprex's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Genprex?

Shares of Genprex can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Genprex's key executives?
Genprex's management team includes the following people:
- Mr. John Rodney Varner Co, Founder, Pres, Chief Executive Officer, Sec. & Chairman(age: 68, pay: $750,940)
- Ms. Catherine M. Vaczy Executive Vice President, Gen. Counsel & Chief Strategy Officer(age: 64, pay: $646,020)
- Mr. Ryan M. Confer M.S. Chief Financial Officer(age: 43, pay: $522,530)
Is Genprex founder-led company?

Yes, Genprex is a company led by its founder Mr. John Rodney Varner.
How many employees does Genprex have?

As Jul 2024, Genprex employs 26 workers, which is 16% less then previous quarter.
When Genprex went public?

Genprex, Inc. is publicly traded company for more then 7 years since IPO on 29 Mar 2018.
What is Genprex's official website?

The official website for Genprex is genprex.com.
Where are Genprex's headquarters?

Genprex is headquartered at 3300 Bee Cave Road, Austin, TX.
How can i contact Genprex?

Genprex's mailing address is 3300 Bee Cave Road, Austin, TX and company can be reached via phone at 877 774 4679.

Genprex, Inc.

genprex.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

877 774 4679

3300 Bee Cave Road
Austin, TX 78746

CIK: 0001595248
ISIN: US3724462037
CUSIP: 372446104